Described herein are compounds, pharmaceutical compositions and methods for treating cancer, inflammation, or autoimmune disease in a subject, or for inhibiting histone methyltransferase G9a.
Described herein are compounds, pharmaceutical compositions and methods for treating cancer, inflammation, or autoimmune disease in a subject, or for inhibiting histone methyltransferase G9a.
Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a
作者:Ramzi F. Sweis、Marina Pliushchev、Peter J. Brown、Jun Guo、Fengling Li、David Maag、Andrew M. Petros、Nirupama B. Soni、Chris Tse、Masoud Vedadi、Michael R. Michaelides、Gary G. Chiang、William N. Pappano
DOI:10.1021/ml400496h
日期:2014.2.13
G9a is a histone lysine methyltransferase responsible for the methylation of histone H3 lysine 9. The discovery of A-366 arose from a unique diversity screening hit, which was optimized by incorporation of a propyl-pyrrolidine subunit to occupy the enzyme lysine channel. A-366 is a potent inhibitor of G9a (IC50: 3.3 nM) with greater than 1000-fold selectivity over 21 other methyltransferases.